In this context, Gallium-68 prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has been developed and increasingly used for accurate staging of high-risk localized, advanced, and metastatic prostate cancer [359]. Here, FOLH1 is linked to metastatic prostate carcinoma.